ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 102 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,949,774 | -34.6% | 3,132,194 | -16.1% | 0.00% | 0.0% |
| Q2 2023 | $28,962,244 | -36.6% | 3,732,248 | -53.4% | 0.00% | 0.0% |
| Q1 2023 | $45,680,930 | +93.1% | 8,014,198 | +99.5% | 0.00% | 0.0% |
| Q4 2022 | $23,657,822 | +70.0% | 4,016,608 | -7.6% | 0.00% | +100.0% |
| Q3 2022 | $13,915,000 | -28.7% | 4,348,392 | -0.2% | 0.00% | -50.0% |
| Q2 2022 | $19,512,000 | -17.3% | 4,355,182 | -1.4% | 0.00% | 0.0% |
| Q1 2022 | $23,594,000 | -72.8% | 4,418,413 | -25.2% | 0.00% | -66.7% |
| Q4 2021 | $86,837,000 | -29.6% | 5,907,279 | +0.2% | 0.01% | -40.0% |
| Q3 2021 | $123,320,000 | +26.6% | 5,897,652 | +7.1% | 0.01% | +25.0% |
| Q2 2021 | $97,372,000 | -27.8% | 5,504,372 | +0.0% | 0.01% | -33.3% |
| Q1 2021 | $134,854,000 | -26.9% | 5,504,252 | +1.0% | 0.01% | -25.0% |
| Q4 2020 | $184,562,000 | +65.9% | 5,452,347 | +21.3% | 0.02% | +45.5% |
| Q3 2020 | $111,226,000 | -19.9% | 4,493,328 | +6.8% | 0.01% | -26.7% |
| Q2 2020 | $138,794,000 | – | 4,206,948 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |